6549.Two
6549.TWO is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotech products and services.
Business. 6549.TWO is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotech products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6549.TWO is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotech products and services.
The company's capital structure is characterized by a high proportion of equity, with total equity of 70,923,000 TWD and total liabilities of 6,325,000 TWD, resulting in a debt-to-equity ratio of 0.03. The company maintains a strong liquidity position, with cash and equivalents amounting to 67,824,000 TWD, and a current ratio of 13.81, indicating a robust ability to meet short-term obligations.
Profitability metrics show a challenging performance, with a return on equity (ROE) of -0.3432 and a return on assets (ROA) of -0.3151, both significantly below the industry median for biotechnology firms. The company reported a net loss of 24,343,000 TWD, and an operating loss of 25,212,000 TWD, reflecting ongoing operational challenges.
Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the absence of revenue figures suggests that the company may be in an early stage of development or experiencing operational disruptions. The lack of segment-specific data limits the ability to assess geographic or product diversification.
The company's growth trajectory is currently negative, with no revenue reported and a net loss in the latest period. The operating cash flow is negative at -24,172,000 TWD, and free cash flow is also negative at -23,022,000 TWD, indicating that the company is not generating sufficient cash from operations to sustain or grow its business.
Risk factors include the company's negative net income and operating income, which could impact its ability to fund operations and meet financial obligations. The company has a low dilution risk, with no immediate filing-based dilution flags detected. However, the negative cash flows and lack of revenue could necessitate future financing, potentially leading to equity dilution.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial statements show consistent losses and negative cash flows, but no major events or disclosures have been reported that would suggest a material change in the company's outlook.
- The company has a strong liquidity position with a current ratio of 13.81 and significant cash reserves.
- The company is currently unprofitable, with a negative return on equity and return on assets.
- The company's financial performance is characterized by negative net income and operating income.
- The company has a low debt-to-equity ratio, indicating a conservative capital structure.
- The company's growth trajectory is negative, with no revenue reported and negative cash flows.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- 6549.TWO Market data — financials · 2026-05-27